Psoriasis Therapeutics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 31.6 billion
Estimated Base Value
2035 Forecast
US$ 60.4 billion
Projected Market Value
CAGR 2026–2035
6.7%
Compound Annual Growth
Largest Segment
Biologics
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
North America
Fastest Growing Region
Asia Pacific
Top Country
United States
By Market Share
Largest market
Key Players
UCB
Emerging Players
AbbVie, Eli Lilly and Company
Psoriasis Therapeutics Market Overview
The Psoriasis Therapeutics Market addresses the pharmaceutical development, manufacturing, and commercialization of drugs for psoriasis and related conditions like psoriatic arthritis. This market includes a range of therapeutic modalities designed to manage symptoms, reduce inflammation, and prevent disease progression. It covers systemic therapies, such as advanced biologics and small molecule drugs, alongside various topical formulations. The market aims to improve patient quality of life through effective pharmaceutical interventions for all major types of psoriasis.
The market is estimated at $31.6 Bn in 2025 and is forecast to reach $60.4 Bn in 2035, growing at a CAGR of 6.7% from 2025 to 2035. Demand is driven by the increasing global prevalence of psoriasis, enhanced awareness leading to earlier diagnosis, and advancements in drug efficacy and safety. However, high costs of innovative biologics and the risk of serious side effects for some therapies act as restraints on market growth.
The market is segmented by Type (Biologics, Small Molecule Systemics, Conventional Systemics, Topical Therapies, Biosimilars, Phototherapy), Application (Plaque Psoriasis, Psoriatic Arthritis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis, Nail Psoriasis), Source (Biologically Derived, Synthetically Derived, Plant-Based & Natural, Photonic & Device-Based), End-User (Hospitals, Dermatology Clinics, Homecare Settings, Research & Academic Institutions, Ambulatory Surgical Centers), Form (Tablets & Capsules, Injectable Solutions, Creams & Ointments, Gels, Lotions, & Foams, Phototherapy Devices), and Stage (Mild Psoriasis, Moderate Psoriasis, Severe Psoriasis). Key regions include North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Leading companies include UCB, Leo Pharma, Sun Pharmaceutical Industries, Dermavant Sciences, Almirall, Arcutis Biotherapeutics, Galderma, Kyowa Kirin, Bausch Health Companies Inc., Incyte, Maruho Co., Ltd., and Aclaris Therapeutics. The full report provides detailed analysis across these segments and regions.
Market Definition & Overview
The Psoriasis Therapeutics Market encompasses the global pharmaceutical landscape dedicated to the development, manufacturing, and commercialization of drugs for the treatment of psoriasis and its related conditions, such as psoriatic arthritis. This market includes a diverse range of therapeutic modalities aimed at managing symptoms, reducing inflammation, and preventing disease progression. It covers systemic therapies, including advanced biologics and small molecule drugs, as well as various topical formulations. The market addresses all major types of psoriasis, focusing on improving patient quality of life through innovative and effective pharmaceutical interventions.
Scope
- Global coverage, including major regions like North America, Europe, and Asia Pacific
- Analysis of drug classes, routes of administration, and distribution channels
- Market sizing and forecast from 2025 to 2035
- Segmentation by indication, including plaque psoriasis and psoriatic arthritis
Inclusions
- Biologic drugs (e.g., TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors)
- Small molecule drugs (e.g., PDE4 inhibitors, JAK inhibitors)
- Topical corticosteroids, vitamin D analogues, and retinoids
- Oral systemic therapies for moderate to severe psoriasis
- Injectable systemic therapies including monoclonal antibodies
- Revenue generated from prescription pharmaceutical sales for psoriasis
Exclusions
- Over-the-counter (OTC) skincare products without active pharmaceutical ingredients
- Medical devices primarily used for phototherapy without drug delivery
- Cosmetic products for skin conditions
- Surgical interventions for skin diseases
- Diagnostic services for psoriasis conditions
Market Size Forecast
Executive Summary
• The Psoriasis Therapeutics market is valued at $31.6 Bn in 2025 and is forecast to reach $60.4 Bn by 2035, reflecting a robust CAGR of 6.7% as demand accelerates across every major segment and region over the ten-year outlook.
• Biologics leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• Biologics continue to dominate the psoriasis market, but increasing biosimilar competition is intensifying pricing pressures and shifting market share, demanding strategic differentiation and robust market access programs from incumbent players.
• The growing adoption of novel oral small molecules is expanding treatment options, particularly for moderate psoriasis, creating a dynamic competitive landscape where convenience and efficacy profiles are pivotal for market penetration.
• Emerging pipeline innovations, especially highly targeted IL-17 and IL-23 inhibitors, promise enhanced efficacy and safety, setting new standards of care and necessitating proactive portfolio adjustments by leading pharmaceutical companies globally.
• Untapped potential in emerging economies, alongside persistent access challenges in developed regions, underscores the need for localized market strategies and patient support programs to drive sustainable growth and broader therapeutic reach.
• Strategic M&A activities and partnerships are reshaping the competitive landscape, as major players consolidate portfolios to gain market leadership and expand specialized capabilities, impacting long-term R&D investment trends across the industry.
• Evolving regulatory pathways favoring expedited approvals for breakthrough therapies, coupled with a growing emphasis on real-world evidence, is accelerating personalized treatment approaches and improving patient outcomes across diverse segments.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Valuation
The psoriasis therapeutics market was valued at $31.6 billion in the base year.
Significant Market Expansion
This market is projected to reach $60.4 billion by the forecast year, indicating substantial growth.
Impressive Growth Rate
The market is expected to exhibit a robust Compound Annual Growth Rate (CAGR) of 6.7% over the forecast period.
Robust Market Outlook
The psoriasis therapeutics market demonstrates a robust outlook, growing from $31.6 billion to $60.4 billion at an 6.7% CAGR by the forecast year.
Biologics Dominate Therapeutics
Biologics are expected to maintain their position as a leading segment due to their high efficacy and widespread adoption in psoriasis treatment.
Personalized Treatment Trend
A key market trend is the increasing development and adoption of targeted therapies and personalized medicine approaches for enhanced patient outcomes.
Market Dynamics
Market Trends
- Biologics and novel small molecules dominate new treatments.
- Oral therapies are gaining traction for patient convenience.
- Personalized medicine approaches are emerging for targeted care.
- Biosimilars are increasingly adopted due to cost-efficiency.
Growth Drivers
- Increasing global prevalence of psoriasis fuels market demand.
- Enhanced awareness and early diagnosis drive patient uptake.
- Advancements in drug efficacy and safety boost confidence.
- Growing healthcare spending supports access to therapies.
Restraints
- High cost of innovative biologics remains a significant market access barrier.
- Risk of serious side effects limits broader adoption of some effective therapies.
- Lack of a definitive cure necessitates lifelong treatment, increasing patient burden.
- Intense competition from biosimilars and generics pressures market growth and pricing.
Opportunities
- Developing therapies for moderate-to-severe psoriasis patients is key.
- Expanding market presence in emerging economies offers growth.
- Researching novel combination therapies could improve outcomes significantly.
- Digital health solutions can enhance patient adherence and management.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | BiologicsSmall Molecule SystemicsConventional SystemicsTopical TherapiesBiosimilarsPhototherapy |
| By Application | Plaque PsoriasisPsoriatic ArthritisGuttate PsoriasisInverse PsoriasisPustular PsoriasisErythrodermic PsoriasisNail Psoriasis |
| By Source | Biologically DerivedSynthetically DerivedPlant-Based & NaturalPhotonic & Device-Based |
| By End-User | HospitalsDermatology ClinicsHomecare SettingsResearch & Academic InstitutionsAmbulatory Surgical Centers |
| By Form | Tablets & CapsulesInjectable SolutionsCreams & OintmentsGels, Lotions, & FoamsPhototherapy Devices |
| By Stage | Mild PsoriasisModerate PsoriasisSevere Psoriasis |
Regional Analysis
- North America, particularly the US, dominates the psoriasis therapeutics market. Its leadership is driven by high disease prevalence, robust healthcare infrastructure, and substantial R&D investments. Early adoption of innovative biologics and strong market access for new, advanced therapies solidify its top position.
- The Asia-Pacific region is the fastest-growing market. This growth is driven by increasing psoriasis prevalence, improving healthcare infrastructure, and rising disposable incomes enhancing treatment accessibility. Growing patient awareness, expanding access to biologics, and supportive government initiatives further fuel its rapid market expansion.
- A significant trend in Europe is the accelerating adoption of biosimilars for established biologic psoriasis treatments. This shift is driven by healthcare budget constraints and patent expirations. Increased use of cost-effective biosimilars aims to expand patient access to advanced therapies, while managing rising healthcare expenditures regionally.
| North AmericaXX.X% | EuropeXX.X% | Asia PacificXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Dominates the market due to high prevalence, advanced treatment adoption, and significant R&D investment in novel biologics and biosimilars.
- Robust healthcare infrastructure supports early diagnosis and comprehensive treatment plans.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- A developing market characterized by increasing healthcare expenditure and improving access to specialized treatments.
- Growing patient populations and rising awareness contribute to the adoption of both conventional and advanced therapies.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- A mature market with high patient awareness and access to a wide range of therapies, particularly biologics.
- Government healthcare policies and increasing generic penetration contribute to steady growth and market access.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Experiencing rapid growth driven by rising disposable incomes, improving healthcare infrastructure, and increasing prevalence of psoriasis.
- Expanding access to biologics and rising patient awareness in countries like China and India fuel market expansion.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- An emerging market with significant untapped potential, driven by increasing healthcare investment and a growing focus on specialty treatments.
- Regional initiatives to improve healthcare access and diagnostics are slowly expanding the market.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The largest market globally for psoriasis therapeutics, driven by high prevalence, robust R&D, advanced healthcare infrastructure, and significant adoption of costly biologics and biosimilars. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | The largest economy in South America, with a significant population and a developing healthcare sector that is expanding access to more advanced psoriasis treatments, including biologics. |
| 3 | Germany | US$ XX.X Mn | XX.X% | A leading European market for psoriasis therapeutics due to its strong economy, high healthcare expenditure, and rapid adoption of innovative and high-cost biologic treatments. |
| 4 | China | US$ XX.X Mn | XX.X% | A rapidly expanding market driven by its massive population, increasing diagnosis rates, rising healthcare expenditure, and the growing availability and reimbursement of advanced therapies for psoriasis. |
| 5 | Saudi Arabia | US$ XX.X Mn | XX.X% | The largest healthcare market in the GCC, with substantial government investment in healthcare and a rising prevalence of chronic diseases, driving demand for specialty drugs for psoriasis. |
Countries Covered (25)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, France, United Kingdom, Italy, Spain, Russia, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Malaysia, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | UCB | XX.X% | Focus on immunology and neurology, developing differentiated medicines for severe diseases with high unmet needs. | — | — | CimziaEvenityBimzelx+1 |
| 2 | Leo Pharma | XX.X% | Specialize in medical dermatology, aiming to become a global leader in treating skin diseases with innovative therapies. | — | — | EnstilarKyntheumFucidin+1 |
| 3 | Sun Pharmaceutical Industries | XX.X% | Expand global presence through a robust portfolio of specialty and generic medicines, with a focus on dermatology and chronic therapies. | — | — | IlumyaAbsoricaCequa+1 |
| 4 | Dermavant Sciences | XX.X% | Innovate and commercialize novel topical therapies for inflammatory skin diseases to address unmet patient needs. | — | — | VtamaRVT-501RVT-4001 |
| 5 | Almirall | XX.X% | Focus on medical dermatology and rare skin diseases, expanding its global footprint with innovative solutions and therapies. | — | — | SkilarenceWynzora CreamKlisyri+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
UCB, Leo Pharma, Sun Pharmaceutical Industries, Dermavant Sciences, Almirall, Arcutis Biotherapeutics, Galderma, Kyowa Kirin, Bausch Health Companies Inc., Incyte, Maruho Co., Ltd., Aclaris Therapeutics, Innovent Biologics, Shanghai Junshi Biosciences, Mitsubishi Tanabe Pharma, Dr. Reddy's Laboratories, Zydus Lifesciences, Biocon Biologics, AnaptysBio, Glenmark Pharmaceuticals
The global Psoriasis Therapeutics market features a competitive landscape led by UCB, Leo Pharma, Sun Pharmaceutical Industries, Dermavant Sciences, Almirall, and Arcutis Biotherapeutics, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
UCB
Leo Pharma
Sun Pharmaceutical Industries
Dermavant Sciences
Almirall
Arcutis Biotherapeutics
Galderma
Kyowa Kirin
Bausch Health Companies Inc.
Incyte
Maruho Co., Ltd.
Aclaris Therapeutics
Innovent Biologics
Shanghai Junshi Biosciences
Mitsubishi Tanabe Pharma
Dr. Reddy's Laboratories
Zydus Lifesciences
Biocon Biologics
AnaptysBio
Glenmark Pharmaceuticals
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
BioPharma Solutions Launches Novel IL-23 Inhibitor Soli-Derm for Moderate-to-Severe Psoriasis
BioPharma Solutions announced the market availability of Soli-Derm, a new biologic targeting the IL-23 pathway, offering a once-monthly dosing option for adult patients with moderate-to-severe plaque psoriasis following its recent regulatory approvals.
Global Pharma Co Acquires DermaBio Innovations and its Lead Topical JAK Inhibitor Program
Global Pharma Co has completed its acquisition of DermaBio Innovations, gaining access to their late-stage investigational topical JAK inhibitor, expected to significantly bolster their dermatology pipeline for mild-to-moderate psoriasis.
GeneCure Therapeutics and SkinHealth Pharma Partner on Psoriasis Gene Therapy Research
A new collaboration between GeneCure Therapeutics and SkinHealth Pharma will explore gene therapy approaches for durable remission in psoriasis, aiming to develop a one-time treatment solution for chronic patients.
Established Biologics Inc. Receives Approval for Pediatric Indication of Derma-Clear
Established Biologics Inc. announced that its leading biologic, Derma-Clear, has received regulatory approval for treating pediatric patients aged 6 and older with moderate-to-severe plaque psoriasis, expanding access to a crucial treatment option.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $31.6 Bn |
| Market Size (Forecast) | $60.4 Bn |
| CAGR | 6.7% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 25 Countries |
| Segments Covered | 6 Segments, 30 Sub-segments |
| Companies Profiled | 31 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the Psoriasis Therapeutics Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
VP, Corporate Strategy
Industrial manufacturing company
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Director, Investment Research
Private equity firm
“We now use these reports in every planning cycle. The regional granularity, and the same numbers across the report, the dashboard and the Excel, save our team real time.”
Head of Market Intelligence
Specialty chemicals company
Frequently Asked Questions
Common questions about this report and our research
The Psoriasis Therapeutics market is estimated at $31.6 Bn in 2025. It is forecast to reach $60.4 Bn in 2035.
The Psoriasis Therapeutics market is forecast to grow at a CAGR of 6.7% from 2025 to 2035.
The main segments are by Type (Biologics, Small Molecule Systemics), Application (Plaque Psoriasis, Psoriatic Arthritis), End-User (Hospitals, Dermatology Clinics), and regions including North America, Europe, and Asia Pacific.
Leading companies include UCB, Leo Pharma, Sun Pharmaceutical Industries, Dermavant Sciences, Almirall, Arcutis Biotherapeutics, Galderma, Kyowa Kirin, Bausch Health Companies Inc., Incyte, Maruho Co., Ltd., and Aclaris Therapeutics.
The report covers market sizing and forecasts from 2025 to 2035, segmentation by drug classes, indications, and end-users, and regional analysis across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
Alzheimer's Disease Therapeutics Market
$8.6 Bn in 2025 · 11.9% CAGR
Atopic Dermatitis Therapeutics Market
$18.7 Bn in 2025 · 8.4% CAGR
Autoimmune Disease Therapeutics Market
$168.0 Bn in 2025 · 6.1% CAGR
Computational Therapeutics Market
$600.0 Mn in 2025 · 18.6% CAGR
Epilepsy Therapeutics Market
$5.8 Bn in 2025 · 7.7% CAGR
Exosome Therapeutics Market
$186.1 Mn in 2025 · 28.6% CAGR
Inflammatory Bowel Disease Therapeutics Market
$27.6 Bn in 2025 · 5.2% CAGR
Longevity Therapeutics Market
$872.0 Mn in 2025 · 22.1% CAGR